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Abstract
Background and Aims: Mesangial C3 deposition is frequently observed in patients with IgA nephropathy (IgAN). However,
the role of complement in the pathogenesis or progression of IgAN is uncertain. In this observational cohort study, we
aimed to identify the clinical implications of circulating C3 levels and mesangial C3 deposition and to investigate their utility
as predictors of renal outcomes in patients with IgAN.
Methods: A total of 343 patients with biopsy-proven IgAN were enrolled between January 2000 and December 2008.
Decreased serum C3 level (hypoC3) was defined as C3 ,90 mg/dl. The study endpoint was end-stage renal disease (ESRD)
and a doubling of the baseline serum creatinine (D-SCr).
Results: Of the patients, there were 66 patients (19.2%) with hypoC3. During a mean follow-up of 53.7 months, ESRD
occurred in 5 patients (7.6%) with hypoC3 compared with 9 patients (3.2%) with normal C3 levels (P = 0.11). However, 12
patients (18.2%) with hypoC3 reached D-SCr compared with 17 patients (6.1%) with normal C3 levels [Hazard ratio (HR),
3.59; 95% confidence interval (CI), 1.33–10.36; P = 0.018]. In a multivariable model in which serum C3 levels were treated as a
continuous variable, hypoC3 significantly predicted renal outcome of D-SCr (per 1 mg/dl increase of C3; HR, 0.95; 95% CI,
0.92–0.99; P = 0.011). The risk of reaching renal outcome was significantly higher in patients with mesangial C3 deposition
2+ to 3+ than in patients without deposition (HR 9.37; 95% CI, 1.10–80.26; P = 0.04).
Conclusions: This study showed that hypoC3 and mesangial C3 deposition were independent risk factors for progression,
suggesting that complement activation may play a pathogenic role in patients with IgAN.
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Introduction
IgA nephropathy (IgAN) is most common primary glomerulo-
nephritis worldwide [1]. Patients with IgAN have a variable
clinical course, ranging from a totally benign condition to
progressive deterioration in kidney function over time. Approxi-
mately 20 to 30% of the patients with IgAN will eventually
develop end stage renal disease (ESRD) within 20 to 25 years after
disease onset [2]. Previous studies have identified clinical and
pathologic features associated with adverse outcomes. These
include heavy proteinuria, reduced renal function, hypertension
at the time of diagnosis, interstitial fibrosis, and glomerular
sclerosis [3–5]. However, there are no available serologic tests that
can be employed to assess disease activity or to predict renal
outcomes in these patients.
Although IgA deposits within the mesangium are a key
diagnostic finding in IgAN, mesangial C3 deposition is also
frequently observed. However, the role of complement activation
in the pathogenesis or progression of IgAN is uncertain [6]. In
previous studies, dimeric and polymeric IgA have been found to
activate complement system in the glomeruli via the alternative or
lectin pathway, thus leading to glomerular damage [7–12]. It was
also reported that systemic complement activation occurs in
patients with IgAN [13,14]. Specifically, Zwirner showed that
activated C3 was associated with increased proteinuria and
subsequent deterioration in kidney function in these patients,
suggesting that systemic complement activation might play a role
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in renal injury in this glomerulopathy [14]. However, their
findings have not yet been validated, thus whether hypocomple-
mentemia may have prognostic value for predicting renal
outcomes is currently unknown. Therefore, we undertook an
observational cohort study to determine the clinical implications of
decreased serum C3 levels (hypoC3) and to investigate its utility as
a predictor of renal outcomes in patients with IgAN. We also
examined clinical features and outcomes according to the
pathologic findings, particularly mesangial C3 deposition in these
patients.
Methods
Ethics statement
The study was carried out in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board of
Yonsei University Health System Clinical Trial Center. We
obtained informed written consent from all participants involved
in our study.
Patients
Renal biopsy was performed in 1181 patients at Yonsei
University Severance Hospital between January 2000 and
December 2008. Among these patients, 436 were diagnosed with
IgAN. Patients with Henoch-Schonlein purpura were considered
ineligible. Our routine practice to assess glomerular disease
encompasses the measurement of serum concentrations of
complement. However, patients in whom serum complement
levels were not available at the time of renal biopsy were excluded
(n = 27). We also excluded patients who had features of IgA-
dominant acute post-infectious glomerulonephritis exhibiting
hypocomplementemia, diffuse glomerular endocapillary hypercel-
lularity, and subepithelial humps on electron microscopy (n= 3)
[15], and patients who had features of lupus nephritis, such as the
presence of typical autoantibodies and ‘‘full house’’ immunoflu-
orescence pattern which was defined as the mesangial co-deposits
of IgG, IgA, IgM, and/or C1q (n= 2) [16]. In addition, patients
with age ,20 years (n = 6) or .75 years (n = 3), inadequate biopsy
sample with the number of glomeruli #7 (n= 7), and patients who
initially presented with nephrotic syndrome (n= 38), crescentic
glomerulonephritis (n = 2), and advanced chronic liver diseases
(n = 5) were also excluded. Therefore, a total of 343 patients were
included in this study (Figure 1).
Data collection
At the time of the renal biopsy, patients’ demographic and
clinical data such as age, gender, blood pressure, episode of gross
hematuria, and presence of hypertension were recorded. Hyper-
tension was defined as systolic blood pressure .140 mmHg or
90 mmHg and the need for antihypertensive medication to
maintain pressures below these levels. In addition, laboratory
parameters such as serum albumin, blood urea nitrogen,
creatinine, uric acid, total cholesterol, triglycerides, C-reactive
protein (CRP) and urinary protein-to-creatinine ratio (UPCR)
were measured. Serum concentrations of immunoglobulins (Igs) A
or G and C3 were measured by immunoturbidimetry (Cobas
C501, Roche, Mannhein, Germany). Using this method, the
normal reference range of C3 levels are 90–180 mg/dl. We
calculated eGFR using the Modification of Diet in Renal Disease
(MDRD) study equation [17].
Renal biopsy
All renal biopsy specimens were re-assessed blindly by a single
pathologist using the Oxford classification [18]. The biopsy
specimens were processed for light microscopy, immunofluores-
cence study, and electron microscopy. IgAN was diagnosed by the
Figure 1. Flow diagram of the study. IgA nephropathy was diagnosed in 436 patients between January 2000 and December 2008. Excluding 93
patients, a total of 343 patients were enrolled. eGFR, estimated glomerular filtration rate; GN, glomerulonephritis; SLE, systemic lupus erythematosus.
doi:10.1371/journal.pone.0040495.g001
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following findings: (1) the presence of predominant IgA deposits (at
least 1+) mainly in the mesangium by immunofluorescence, (2) the
presence of mesangial electron-dense deposits by electron micro-
scopic examination, and (3) the absence of other systemic
inflammatory diseases such as systemic lupus erythematosus. The
mesangial hypercellularity score was preferred to the percentage of
glomeruli showing severe mesangial hypercellularity. The cutoff
for the mesangial hypercellularity score was 0.5. Segmental
glomerulosclerosis and endocapillary hypercellularity were cate-
gorized as either present or absent. Tubular atrophy/interstitial
fibrosis was classified as T0 (0–25% of cortical area), T1 (26–50%
of cortical area), or T2 (.50% of cortical area) [18]. We quantified
the immunofluorescence staining of C3 deposition in the
mesangial area by ImageJ software v1.60 (NIH, Bethesda,
Maryland, USA; online at http://rsbweb.nih.gov/ij). With the
use of this method, quantification of immunofluorescence was
expressed as arbitrary unit (AU), which was calculated as (mean
pixel intensity X glomerular area)/100,000. Mesangial C3 deposits
were classified into four groups: 0, AU level ,5; 1+, 5# AU level
,20; 2+, 20# AU level ,40; and 3+, 40# AU level (Figure 2).
Study outcomes
The study endpoint was ESRD and a doubling of the baseline
serum creatinine (D-SCr). ESRD was defined as initiation of renal
replacement therapy including permanent hemodialysis, peritone-
al dialysis, or renal transplantation. We also evaluated the decline
rate of eGFR between patients with hypoC3 and patients with
normal C3 levels.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0
(SPSS Inc., Chicago, Illinois, USA). Continuous data were
expressed as mean 6 SD, and categorical data were expressed
as a number (percentage). The two groups were compared using
the t-test or chi-squared test. The Kolmogorov-Smirnov test was
used to analyze the normality of the distribution of parameters.
Nonparametric variables were expressed as median and inter-
quartile range and compared using the Mann–Whitney test or
Kruskal–Wallis test. Probability of renal survival curves were
generated by the Kaplan-Meier method, and between-group
survival was compared by the log-rank test. The independent
prognostic values of clinical and pathological parameters for the
study outcomes were analyzed by multiple Cox regression
analyses. Hazard ratios (HRs) and 95% confidence intervals
(CIs) were calculated with the use of the estimated regression
coefficients and standard errors in the Cox regression analysis.
The predictive value for renal outcome was also analyzed by
receiver operating characteristic (ROC) curve analysis with
calculated area under the ROC curve (AUC). Finally, to compare
Figure 2. Representative pictures of immunofluorescence staining of mesangial C3 1+ to 3+. Immunofluorescence intensity was
quantified by ImageJ software.
doi:10.1371/journal.pone.0040495.g002
Figure 3. A scattered plot of each level of serum C3 between
patients with C3 levels ,90 mg/dl and patients with C3 levels
$90 mg/dl.
doi:10.1371/journal.pone.0040495.g003
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the decline rate of eGFR between the two groups, multivariate
linear regression analysis was conducted. All probabilities were
two-tailed and the level of significance was set at 0.05.
Results
Baseline characteristics
The demographic, clinical, and biochemical characteristics of
the study population are shown in Table 1. Of the 343 patients, 66
patients (19.2%) had C3 levels below the lower limit of the normal
range (,90 mg/dl) and were considered to have hypoC3. A
Table 1. Demographic, clinical and biochemical characteristics.
All (n = 343) C3 ,90 mg/dl (n =66) C3 $90 mg/dl (n=277) P-value
Age (years) 34.5611.7 31.169.2 35.4612.1 0.002
Male gender (n, %) 159 (46.4%) 30 (45.5%) 129 (46.6%) 0.87
Hypertension (n, %) 85 (24.8%) 8 (12.1%) 77 (27.8%) 0.008
Diabetes (n, %) 4 (1.2%) 1 (1.5%) 3 (1.1%) 0.77
Coronary artery disease (n, %) 8 (2.3%) 2 (3.0%) 6 (2.2%) 0.68
Hepatitis B antigen positivity (n, %) 15 (4.4%) 2 (3.2%) 13 (5.1%) 0.74
Hepatitis C antibody positivity (n, %) 1 (0.3%) 0 (0%) 1 (0.6%) 1.00
Episodes of gross hematuria (n, %) 93 (27.1%) 16 (24.2%) 77 (27.8%) 0.56
Body mass index (kg/m2) 22.763.3 20.962.4 23.263.3 ,0.001
Systolic blood pressure (mmHg) 125.7615.3 121.5611.1 126.8616.0 0.002
141 to 160 mmHg (n, %) 34 (9.9%) 7 (10.6%) 27 (9.7%)
161 to 180 mmHg (n, %) 2 (0.6%) 0 (0%) 2 (0.7%)
.180 mmHg (n, %) 2 (0.6%) 0 (0%) 2 (0.7%)
MAP (mmHg) 94.2611.4 91.469.5 94.8611.7 0.031
Blood urea nitrogen (mg/dl) 15.065.6 15.266.4 15.065.5 0.74
Creatinine (mg/dl) 1.160.4 1.160.4 1.160.4 0.34
eGFR (ml/min/1.73 m2) 79.8624.2 78.8626.1 80.0623.8 0.71
eGFR ,30 (n, %) 9 (2.6%) 3 (4.5%) 6 (2.2%)
30# eGFR ,60 (n, %) 65 (19.0%) 15 (22.7%) 50 (18.1%)
eGFR $60 (n, %) 269 (78.4%) 48 (72.7%) 221 (79.8%)
Protein (g/dl) 6.860.6 6.660.6 6.860.6 0.10
Albumin (g/dl) 4.160.5 4.060.5 4.160.5 0.10
Uric acid (mg/dl) 5.761.6 5.661.7 5.861.6 0.45
Cholesterol (mg/dl) 181.8638.5 170.8639.9 184.4637.8 0.01
Triglycerides (mg/dl) 132.3691.0 106.1650.1 139.2697.9 0.002
Urine PCR (mg/mg) 1.361.4 1.261.4 1.461.4 0.34
IgG (mg/dl) 1238.76301.2 1200.76294.2 1247.96302.9 0.30
IgA (mg/dl) 309.56103.8 296.5695.8 312.76105.7 0.28
C3 (mg/dl) 104.2617.1 82.066.8 109.5614.3 ,0.001
C-reactive protein (mg/l)* 1.0 (0.3–2.72) 1.0 (0.5–1.3) 1.1 (0.5–3.1) 0.53
Medications
ACE inhibitors or ARBs 215 (62.7%) 39 (59.1%) 176 (63.5%) 0.50
Diuretics 60 (17.5%) 7 (10.6%) 53 (19.1%) 0.09
Other antihypertensive drugs 53 (15.5%) 6 (9.1%) 47 (17.0%) 0.11
More than 2 antihypertensive drugs 50 (14.6%) 6 (9.1%) 44 (15.9%) 0.16
More than 3 antihypertensive drugs 18 (5.2%) 1 (1.5%) 17 (6.1%) 0.22
HMG-CoA reductase inhibitors 49 (14.3%) 6 (9.1%) 43 (15.5%) 0.18
Corticosteroid 10 (2.9%) 2 (3.0%) 8 (2.9%) 0.95
Cyclosporine 3 (0.9%) 0 (0%) 3 (1.1%) 0.40
Time to renal biopsy (months)* 12 (3–36) 11 (3–30) 12 (3–36) 0.48
Data are presented as n (%) or mean 6 SD or *median and interquartile range.
MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; PCR, protein to creatinine ratio; Ig, immunoglobulin; C, complement; ACE, angiotensin
converting enzyme; ARB, angiotensin II receptor blocker.
doi:10.1371/journal.pone.0040495.t001
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scattered plot of each level of serum C3 was presented in Figure 3.
Compared to patients with C3 $90 mg/dl, those with C3
,90 mg/dl were younger (31.169.2 vs. 35.4612.1 years,
P = 0.002) and had lower mean arterial blood pressure
(91.469.5 vs. 94.8611.7 mmHg, P= 0.031). Patients with uncon-
trolled hypertension were more common in patients with C3
$90 mg/dl. Of note, these patients had higher BMI, and
cholesterol and triglyceride levels than patients with C3 levels
,90 mg/dl (Table 1). Between the two groups, however there
were no differences in eGFR, UPCR, Ig levels, CRP, comorbid-
ities, or medications including immuno-suppressants and antihy-
pertensive agents during follow-up. Meanwhile, no patients
underwent tonsillectomy for the prevention of disease progression
in our study.
In patients with nephrotic syndrome, serum C3 levels were
97.8614.7 mg/dl and 6 (15.8%), 25 (65.7%), and 7 (18.4%)
patients had mesangial C3 deposits of 0, 1+, and 2+ or more,
respectively. Whether complement activation is involved in the
development of nephrotic syndrome in IgA nephropathy is
currently unknown. We recently demonstrated that IgAN patients
with nephrotic syndrome exhibited different features and had
worse prognosis compared with patients with typical IgA
nephropathy [19]. In addition, they are usually more likely to be
treated with immunosuppressive drugs. These may lead to a biased
result, thus patients with nephrotic syndrome were excluded from
the analysis.
Pathologic findings
The histopathologic features from renal biopsies between
patients with and without hypoC3 are presented in Table 2.
Patients with hypoC3 had higher grade mesangial deposition of
C3 (2+ to 3+) than those without hypoC3 (28.8 vs. 18.8%,
P= 0.011). There were no differences in mesangial hypercellular-
ity, glomerulosclerosis, endocapillary hypercellularity, tubulointer-
Figure 4. The histopathologic grades such as (A) mesangial hypercellularity, (B) segmental glomerulosclerosis, (C) endocapillary
hypercellularity, and (D) tubular atrophy/interstitial fibrosis according to mesangial C3 deposition. Mesangial hypercellularity (C3
deposition 0, 9.4%; 1+, 29.7%; 2+,3+, 49.3%; P,0.001) and high-grade tubular atrophy/interstitial fibrosis (C3 deposition 0, 7.5%; 1+, 10.5%; 2+,3+,
14.1%; P,0.001) were more prominent as the mesangial area of C3 deposition increased.
doi:10.1371/journal.pone.0040495.g004
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stitial lesions, arteriosclerosis, and mesangial deposition of IgG or
IgA between the two groups (Table 2). The histopathologic
features were further compared according to mesangial C3
deposition. Mesangial hypercellularity (C3 deposition 0, 9.4%;
1+, 29.7%; 2+,3+, 49.3%; P,0.001) and high-grade tubular
atrophy/interstitial fibrosis (C3 deposition 0, 7.5%; 1+, 10.5%;
2+,3+, 14.1%; P,0.001) were more prominent as the mesangial
area of C3 deposition increased (Figure 4). However, there was no
significant difference in segmental glomerulosclerosis or endoca-
pillary hypercellularity. On the other hand, serum C3 levels
decreased significantly from 0 to 2+,3+ mesangial C3 deposition
(0, 111.7618.0; 1+, 104.3617.1; 2+,3+, 98.6614.2 mg/dl;
P,0.001) (Figure 5).
Renal Outcomes
During a mean follow-up of 53.7630.1 months, 14 (4.1%)
developed ESRD and 29 patients (8.5%) reached the end point of
doubling of the baseline serum creatinine levels. There was no
patient who progressed to ESRD before reaching doubling of the
baseline serum creatinine. ESRD occurred in 5 patients (7.6%)
with hypoC3 compared with 9 patients (3.2%) with normal C3
levels (P = 0.11, Table 3). However, 12 patients (18.2%) with
hypoC3 reached D-SCr compared with 17 patients (6.1%) with
normal C3 levels (HR, 3.59; 95% CI, 1.56–8.28; P= 0.003)
(Table 3 and Table 4, Model 1) and a 10-year renal survival rate
was significantly lower in the former (Figure 6A, P= 0.006). In
addition, the expanded mesangial deposition of C3 was associated
with worse renal survival (Figure 7B). ESRD occurred in 1 (1.9%),
9 (4.1%), and 4 (5.6%) patients with mesangial C3 deposition of 0,
1+, and 2+ to 3+, respectively (P = 0.30, Table 3). However, the
risk of reaching D-SCr was significantly higher in patients with
mesangial C3 deposition 2+ to 3+ than in patients without
deposition (HR 14.24; 95% CI, 2.03–99.87; P= 0.008) (Table 4,
Model 2). In a multivariable model in which serum C3 levels were
treated as a continuous variable, hypoC3 significantly predicted
renal outcome of D-SCr (per 1 mg/dl increase of C3; HR, 0.96;
95% CI, 0.93–0.98; P = 0.002) (Table 4, Model 1). When both
serum C3 levels and mesangial C3 deposition were included in a
multivariate model, these two parameters remained independent
predictors of adverse renal outcomes (Table 4, Model 3 and 4). In
ROC curve analysis, serum C3 levels had a significant predictive
value for the renal outcome (AUC=0.642, P= 0.011), although
the predictive value of serum C3 was lower than UPCR
(AUC=0.819, P,0.001) or eGFR (AUC=0.781, P,0.001)
(Figure 6). On the other hand, patients with mesangial hypercel-
lularity, segmental glomerulosclerosis, endocapillary proliferation,
and tubular atrophy/interstitial fibrosis had significantly lower
renal survival than those without such findings (P,0.05) (Figure 8).
In the multivariate linear regression analysis adjusted for
clinical, laboratory, and histologic factor, the decline rate of
eGFR was greater in patients with hypoC3 than in patients with
normal C3 levels only up to 4 years after the diagnosis. However,
overall decline rate of eGFR did not differ between the two groups
(Figure 9).
Discussion
This study showed that both decreased circulating C3 levels and
mesangial C3 deposition were associated with deterioration of
kidney function in patients with IgAN independent of heavy
proteinuria and other unfavorable histopathologic features such as
glomerular sclerosis or interstitial fibrosis. Our findings suggest
that decreased serum C3 levels and C3 deposition within the
mesangium may provide prognostic value in these patients.
In patients with IgAN, O-linked carbohydrates in the hinge
region of IgA1 molecule are under-galactosylated and defective
IgA1 forms circulating or in situ immune complexes [20].
Subsequent deposition of immune complexes within the mesan-
gium plays a key role in the pathogenesis of IgAN. Interestingly,
mesangial C3 deposits are often observed along with IgA,
suggesting that complement activation may also be involved in
pathogenesis. In fact, many studies have previously suggested that
local complement system in the glomeruli is activated via the
alternative or the mannose-binding lectin (MBL) pathway in IgAN
[7–12]. Although there is a general agreement that C3 deposits are
caused predominantly by complement activation via the alterna-
tive pathway in IgAN, several studies have recently suggested that
the lectin pathway of complement may also be involved in the
progression of disease [10–12]. In particular, Roos et al. reported
that activation of the lectin pathway was associated with more
severe renal damage in IgAN [11]. In their study, complement
activation occurred via the alternative pathway in 75% of patients
whereas glomerular deposition of MBL, L-ficolin, and C4d, which
was indicative of activation of complement via the lectin pathway,
was observed in 25% of patients [11]. However, it is uncertain
whether such complement activation may affect the long-term
outcomes in patients with IgAN. Komatsu et al. showed that C3
deposition within the mesangium significantly correlated with
severe histologic lesions using kidney specimens from patients with
IgAN [21]. In line with their findings, in the present study, we
clearly showed that patients with higher grade mesangial
deposition of C3 had worse histologic findings such as mesangial
hypercellularity and tubular atrophy/interstitial fibrosis than those
with lower grade deposition. Because such histologic features are
apparently associated with worse prognosis [22,23], it can be
presumed that patients with mesangial C3 deposition have worse
renal outcomes compared with those without deposition as seen in
our study. Taken together, it can be suggested that complement
activation may mediate further renal injury and that mesangial C3
deposition may have prognostic value in IgAN.
Figure 5. Comparison of serum C3 levels according to
mesangial C3 deposition. Serum C3 levels decreased significantly
from 0 to 2+,3+ mesangial C3 deposition (0, 111.7618.0; 1+,
104.3617.1; 2+,3+, 98.6614.2 mg/dl; P,0.001).
doi:10.1371/journal.pone.0040495.g005
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Although previous studies demonstrated that complement
activation occurred locally in IgAN, several studies reported that
systemic complement activation may also be present [13,14]. In
particular, Zwirner et al. showed that activated C3 levels in the
plasma were elevated in patients with IgAN and correlated with
deterioration in renal function [14], suggesting that systemic
complement activation may also be involved in the progression of
IgAN. However, measurement of activated C3 is not widely
available because slow ex vivo generation of activated C3 can be
observed even during storage at 270uC [24]. Consumption of
complement factors is reflected by either decreased levels of
individual proteins such as C3 and C4 or depressed total
complement hemolytic activity (CH50), as well as the production
of complement activation split products [25]. In this regard,
decreased serum C3 levels in our 66 patients are possibly due to
C3 consumption due to systemic complement activation although
other components of complement cascade and C3 splits were not
measured. To date, clinical implication of decreased serum C3
levels in patients with IgAN has not yet been explored. Several
Japanese studies have examined the clinical utility of C3. Tomino
et al. showed that serum IgA/C3 ratio might be of help in
diagnosing IgAN [26]. In addition, renal survival was significantly
decreased in patients with a higher serum IgA/C3 ratio than those
with a lower ratio [21]. Interestingly, in a study by Komatsu et al.,
serum C3 levels were decreased in patients with IgAN with severe
histologic lesions compared with those seen in non-IgAN.
Unfortunately, they did not assess the prognostic value of
decreased serum C3 levels. In the present study, we showed for
the first time that patients with decreased serum C3 levels had
worse renal survival than those with higher C3 levels. Moreover,
decreased serum C3 levels were independently predictive of renal
outcome in the multivariate analysis even after adjustment for
factors known to be associated with worse prognosis such as
proteinuria and decreased renal function at presentation although
predictive value of low C3 levels were not so potent as these
conventional factors. It should be noted that many physicians are
Table 2. Comparison of histopathologic features from renal biopsies between patients with and without decreased C3 levels.
All (n =343) C3 ,90 mg/dl (n=66) C3 $90 mg/dl (n =277) P-value
Mesangial hypercellularity 0.81
#50% of the glomeruli (M0) 238 (69.4%) 45 (68.2%) 193 (69.7%)
.50% of the glomeruli (M1) 105 (30.6%) 21 (31.8%) 84 (30.3%)
Segmental glomerulosclerosis 0.30
Absent (S0) 261 (76.1%) 47 (71.2%) 214 (77.3%)
Present (S1) 82 (23.9%) 19 (28.8%) 63 (22.7%)
Endocapillary hypercellularity 0.16
Absent (E0) 324 (94.5%) 60 (90.9%) 264 (95.3%)
Present (E1) 19 (5.5%) 6 (9.1%) 13 (4.7%)
Tubular atrophy/interstitial fibrosis 0.07
0–25% of cortical area (T0) 148 (43.1%) 23 (34.8%) 125 (45.1%)
25–50% of cortical area (T1) 158 (46.1%) 31 (47.0%) 127 (45.8%)
.50% of cortical area (T2) 37 (10.8%) 12 (18.2%) 25 (9.0%)
Arteriosclerosis 70 (20.4%) 12 (18.2%) 58 (20.9%) 0.62
Mesangial IgG deposition (n, %) 0.45
Negative 204 (59.5%) 36 (54.5%) 168 (60.6%)
1+ 126 (36.7%) 26 (39.4%) 100 (36.1%)
2+ 11 (3.2%) 4 (6.1%) 7 (2.5%)
3+ 2 (0.6%) 0 (0.0%) 2 (0.7%)
2+ and 3+ 13 (3.8%) 4 (6.1%) 9 (3.2%)
Mesangial IgA deposition (n, %) 0.77
1+ 104 (30.3%) 21 (31.8%) 83 (30.0%)
2+ 168 (49.0%) 29 (43.9%) 139 (50.1%)
3+ 71 (20.7%) 16 (24.3%) 55 (19.9%)
2+ and 3+ 239 (69.7%) 45 (68.2%) 194 (70.0%)
Mesangial C3 deposition (n, %) 0.011
Negative 53 (15.5%) 3 (4.5%) 50 (18.1%)
1+ 219 (63.8%) 44 (66.7%) 175 (63.2%)
2+ 63 (18.4%) 16 (24.3%) 47 (17.0%)
3+ 8 (2.3%) 3 (4.5%) 5 (1.8%)
2+ and 3+ 71 (20.7%) 19 (28.8%) 52 (18.8%)
Data are presented as n (%).
Ig, immunoglobulin; C, complement.
doi:10.1371/journal.pone.0040495.t002
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not aware of the significance of decreased serum C3 levels in
patients with IgAN although hypoC3 is not common. In this
regard, our findings deserve particular attention because decreased
serum C3 levels may be another useful biomarker to predict
progression of IgAN.
In contrast to findings by Tomino et al, in this study, IgA/C3
ratio had a trend toward poor renal outcome, but it did not reach
statistical significance (data not shown). This can be explained by
the fact that simply elevated IgA levels cannot reflect disease
activity. In fact, although circulating IgA levels are elevated in
patients with IgAN, correlation of the elevated IgA levels with
clinical features of the disease is inconsistent [27,28]. Interestingly,
40 to 50% of first degree relatives of IgAN patients have elevated
IgA levels, but most of these persons do not exhibit clinical sings of
renal injury [29,30]. These findings suggest that additional
pathogenic factors such as generation of antibodies against IgA
or immune-complex formation are required to activate the disease.
It is uncertain whether systemic and local activation of
complement system coordinate together or if they exert indepen-
dent effects although both types of activation have been previously
Figure 6. Kaplan-Meier analyses of cumulative renal survival of patients with IgA nephropathy based on (A) serum C3 level and (B)
mesangial C3 deposition. (A) A 10-year renal survival rate was significantly lower in patients with C3 levels ,90 mg/dl than those with C3 levels
$90 mg/dl (P = 0.006). (B) A 10-year survival in patients with 2+ and 3+ mesangial deposition of C3 was lower than in those without C3 deposition
(P = 0.04).
doi:10.1371/journal.pone.0040495.g006
Figure 7. ROC curve analysis for renal outcome of the doubling of the baseline serum creatinine. Serum C3 levels had a significant
predictive value for renal outcome (AUC=0.642, P = 0.011), although the predictive value of serum C3 was lower than UPCR (AUC= 0.819, P,0.001)
or eGFR (AUC= 0.781, P,0.001).
doi:10.1371/journal.pone.0040495.g007
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reported in IgAN [7–14]. Activation of the complement system
was common in patients with systemic lupus erythematosus (SLE),
leading to hypocomplementemia and deposition of complement
component at sites of tissue injury, particularly in the glomeruli
and the skin [31]. This finding suggests that complement
activation likely has a role in tissue damage in SLE. In addition,
some studies reported that the lectin pathway of the complement
system is activated in rheumatoid arthritis. Although levels of
lectin pathway proteins were higher in plasma than synovial fluid,
paired plasma and synovial fluid levels correlated significantly in
all cases [32]. Consistent with these findings, our study showed
that serum C3 levels correlated with mesangial C3 deposition,
suggesting a possible link between the two complement systems.
Despite such a correlation, it is possible that both factors may be
independently associated with poor renal survival because there
was no significant interaction on multivariable Cox regression
analysis (data not shown). However, due to the observational
nature of the study, it is difficult to clarify how systemic
complement activation is involved in local activation.
Interestingly, in this study, patients with C3 $90 mg/dl had
higher BMI, blood pressure, and cholesterol levels. Recent
previous studies showed that increased complement levels were
related to extreme adiposity and insulin resistance [33,34]. On the
contrary, a few studies suggested complement activation in
patients with very low BMI such as anorexia nervosa [35–37].
All these patients exhibited decreased C3 levels, which might
reflect severe comorbid conditions such as malnutrition. However,
in this study, it is uncertain whether C3 levels were affected by
Figure 8. Kaplan-Meier analyses of cumulative renal survival of patients with IgA nephropathy according to histopathologic
features including (A) mesangial hypercellularity, (B) segmental glomerulosclerosis, (C) endocapillary hypercellularity, and (D)
tubular atrophy/interstitial fibrosis. Patients with mesangial hypercellularity, segmental glomerulosclerosis, endocapillary hypercellularity, and
tubular atrophy/interstitial fibrosis had significantly lower renal survival than those without such findings (P,0.05).
doi:10.1371/journal.pone.0040495.g008
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obesity or nutritional status. Mean BMI of the study subjects were
22.7 kg/m2 and there were only 12 patients with BMI.30 kg/m2.
Even patients with C3 $90 mg/dl had a mean BMI of 23.2 kg/
m2, suggesting that they were not obese. In addition, serum
albumin level, which is a good indicator of nutritional status, did
not differ between patients with hypoC3 and patients with C3
$90 mg/dl. Nevertheless, to examine possible effects of these
factors on outcome, we conducted a Cox regression model further
adjusted for BMI, cholesterol, and serum albumin and found that
decreased C3 levels and mesangial C3 deposits remained
significant predictors of renal outcome (Table 4, Model 4).
Not surprisingly, we confirmed that unfavorable histologic
features such as mesangial hypercellularity, glomerulosclerosis,
and tubular atrophy/interstitial fibrosis, which were previously
reported to be poor prognostic factors, were significantly
associated with adverse renal outcomes. However, it is unclear
how glomerulopathy associated with mesangial IgA deposition
leads to tubulointerstitial injury although tubulointerstitial lesions
are common in IgAN [38]. It is possible that glomerulotubular
cross-talk with mediators such as cytokines, complement, and
angiotensin II may contribute to the pathogenesis of tubulointer-
stitial damage in IgAN as suggested by Chan et al. [39].
Interestingly, in the present study, the severity of tubulointerstitial
lesions was associated with the expansion of mesangial C3
deposition. This finding suggests that complement activation
may aggravate glomerular injury, eventually resulting in the
development of tubulointerstitial damage, and that the comple-
ment system may act as a mediator in glomerulotubular cross-talk.
Recent studies showed that other pathologic features such as
wide areas of electron dense deposits [40] and thrombotic
microangiopathy [41] were associated with adverse outcome in
IgAN. Detailed analysis on relationship between mesangial C3
deposition and these pathologic features is beyond the scope of this
study. However, we found that there was no correlation between
intensity of C3 deposits and areas of electron dense deposits
although electron dense deposits were observed in other areas
besides paramesangial area. It is possible that complement
activation in response to immune complex may differ depending
on mesangial or paramesangial areas. In addition, thrombotic
microangiopathy was found in only 25 (7.3%) patients, which is
quite low compared with 53% in a study by Karoui et al. This is
probably because our study subjects were relatively young and
blood pressure was well controlled. In fact, in a study by Karoui et
al, 71% had uncontrolled hypertension, which was associated with
thrombotic microangiopathy. In contrast, only 38 (11.1%) patients
in our study had systolic blood pressure .140 mmHg and
intensity C3 deposits were not related with thrombotic microan-
giopathy. Furthermore, Karoui et al. found no genetic mutation of
complement factor H and I in patients with severe thrombotic
microangiopathy, suggesting the alternative pathway is less likely
involved in this lesion. Whether complement activation can
contribute to more depositions of immune-complex besides
paramesangial area or thrombotic microangiopathy requires
further in-depth investigations.
Limitations
Our study had several limitations. First, this was a retrospective
study, thus the observational nature of the present study limits our
findings suggesting that complement activation actually contrib-
utes to the progression of IgAN. Second, other complement
components including activated C3, C4-C3 complexes, or soluble
C5b-9 were not available. We also did not perform the additional
staining for MBL, C4d, and C3c in glomeruli, which were
previously suggested to be possible predictors of disease activity as
alternatives to C3 [9,12]. Third, serum C3 levels were only
measured at the time of renal biopsy. Thus, whether hypoC3
persisted throughout the disease course is unknown. Interestingly,
there were five patients who had follow-up data for serum C3
levels with a median duration of 22 months. They had persistently
decreased serum C3 levels and four of them reached the doubling
of the baseline serum creatinine. Therefore, it would be helpful to
monitor the level serially to further clarify the clinical implications
of hypoC3 in IgAN. Fourth, serum C3 levels and mesangial C3
deposition were not associated with the development of ESRD.
This finding is partly due to the fact that ESRD occurred in only
14 patients (4.2%) during the follow-up period, thus resulting in a
lack of statistical power. In addition, overall decline rate of eGFR
did not differ between patients with hypoC3 and patients with
normal C3 levels. It should be noted that most patients with
hypoC3 reached the endpoints within 4 years after the baseline
evaluation. This can explain the faster decline in eGFR in these
patients until 4 years. However, it is possible that small number of
events did not have adequate statistical power to see the difference
in eGFR decline. Fifth, the presence of other diseases exhibiting
both hypoC3 and mesangial IgA deposition could not entirely be
excluded. However, we conducted a thorough pathologic exam-
ination and excluded patients with conditions such as systemic
lupus erythematosus and IgA-dominant acute post-infectious
glomerulonephritis. Moreover, we confirmed that autoantibodies
such as antinuclear antibody or anti-DNA antibody were negative
in all patients with hypoC3. Sixth, intensity of immunofluores-
cence may not be correct because of different condition of
immunofluorescent staining, storage time, or altered antigenicity
of immune complex by environmental proteases. However, in our
Table 3. Incidence of patients with doubling of serum creatinine and ESRD according to decreased C3 levels and mesangial C3
deposition.
Serum C3 Mesangial C3 deposition
C3 ,90 mg/d C3 $90 mg/dl P-value C3(2) C3(+) C3(2+,3+) P-value
N (%)
/1000
patient
-years N (%)
/1000
patient
-years N (%)
/1000
patient
-years N (%)
/1000
patient
-years N (%)
/1000
patient
-years
ESRD 5 (7.6%) 15.67 9 (3.2%) 7.57 0.11 1 (1.9%) 5.05 9 (4.1%) 9.30 4 (5.6%) 11.73 0.30
Doubling
of Scr
12 (18.2%) 34.48 17 (6.1%) 12.62 0.002 2 (3.8%) 5.05 16 (7.3%) 15.50 11 (15.5%) 29.33 0.016
ESRD, end-stage renal disease; C, complement; N, number; Scr, serum creatinine.
doi:10.1371/journal.pone.0040495.t003
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institute, immunofluorescence pictures were generally taken
immediately after biopsy samples were processed. Furthermore,
to quantify the immunofluorescence intensity, these pictures were
converted to digital images and analyzed using ImageJ software.
Table 4. Cox regression models for renal outcome of the doubling of the baseline serum creatinine.
HR 95% CI P-value HR 95% CI P-value
Model 1
eGFR (per 1 ml/min/1.73 m2 increase) 0.96 0.93–0.98 ,0.001 0.95 0.93–0.98 ,0.001
Urinary PCR (per 1 mg/mg increase) 1.70 1.36–2.12 ,0.001 1.52 1.26–1.82 ,0.001
Serum C3 (per 1 mg/dl increase) 0.96 0.93–0.98 0.002 - - -
Patients with hypoC3 (vs. no) - - - 3.59 1.56–8.28 0.003
Model 2
eGFR (per 1 ml/min/1.73 m2 increase) 0.97 0.95–0.99 0.037 - - -
Urinary PCR (per 1 mg/mg increase) 1.63 1.27–2.08. ,0.001 - - -
Tubular atrophy/interstitial fibrosis - - -
0–25% of cortical area (T0) Reference
25–50% of cortical area (T1) 7.632 0.91–63.6 0.061 - - -
.50% of cortical area (T2) 35.81 4.03–217.9 0.001 - - -
Mesangial C3 deposition
0 Reference
1+ 6.03 0.93–39.00 0.059 - - -
2+,3+ 14.24 2.03–99.87 0.008 - - -
Model 3
eGFR (per 1 ml/min/1.73 m2 increase) 0.98 0.95–0.99 0.038 0.97 0.95–0.99 0.031
Urinary PCR (per 1 mg/mg increase) 1.86 1.42–2.44 ,0.001 1.71 1.32–2.21 ,0.001
Tubular atrophy/interstitial fibrosis
0–25% of cortical area (T0) Reference Reference
25–50% of cortical area (T1) 8.20 0.97–69.4 0.053 8.50 1.01–71.43 0.049
.50% of cortical area (T2) 35.26 4.04–207.5 0.001 34.90 3.93–209.9 0.001
Mesangial C3 deposition
0 Reference Reference
1+ 3.75 0.63–22.3 0.147 5.64 0.80–39.55 0.082
2+,3+ 8.76 1.39–55.2 0.021 14.03 1.86–105.77 0.010
Serum C3 (per 1 mg/dl increase) 0.95 0.93–0.98 0.004 - - -
Patients with hypoC3 (vs. no) - - - 3.35 1.41–7.99 0.006
Model 4
eGFR (per 1 ml/min/1.73 m2 increase) 0.97 0.95–0.99 0.030 0.97 0.95–0.99 0.021
Urinary PCR (per 1 mg/mg increase) 1.78 1.29–2.46 ,0.001 1.65 1.21–2.26 0.002
Tubular atrophy/interstitial fibrosis
0–25% of cortical area (T0) Reference Reference
25–50% of cortical area (T1) 8.14 0.94–70.59 0.057 8.09 0.94–69.6 0.057
.50% of cortical area (T2) 32.41 3.61–191.44 0.002 30.42 3.31–179.2 0.003
Mesangial C3 deposition
0 Reference Reference
1+ 4.58 0.62–33.70 0.135 7.25 0.69–58.89 0.064
2+,3+ 10.17 1.33–77.9 0.026 16.18 1.89–138.36 0.011
Serum C3 (per 1 mg/dl increase) 0.96 0.93–0.99 0.019 - - -
Patients with hypoC3 (vs. no) - - - 2.73 1.09–6.86 0.032
Data are reported as hazard ratio (HR) and 95% confidence interval (CI).
Model 1: age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment, and serum C3 levels.
Model 2: age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment, and pathologic findings.
Model 3: Model 2+serum C3 levels.
Model 4: Model 3+BMI, total cholesterol, and serum albumin.
eGFR, estimated glomerular filtration rate; PCR, protein-to-creatinine ratio.
doi:10.1371/journal.pone.0040495.t004
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Seventh, serum C3 levels were mildly decreased in 66 patients with
hypoC3, suggesting that the disease may not truly be a ‘flare-up’,
which can be seen in severe lupus nephritis [42]. It is unknown
whether such a mild decrease in C3 levels may affect the clinical
outcomes. Considering the fact that IgAN exhibits a slowly
progressive course, it is possible that indolent inflammatory
process is still underway even in such a mild hypoC3status. Based
on our finding that renal survival rate was lower in patients with
hypoC3 compared to those with normal C3 levels although no
significant difference in baseline histopathologic features was
observed, we surmise that complement activation may contribute
to the development of slowly progressive renal injury for an
extended period of time. Finally, clinical significance of C3 levels
was reported mostly from studies involving Asian population
[21,26]. In addition, a prior study suggested a geographical
variability in long-term outcomes of IgA nephropathy [43].
Therefore, our results may not be extrapolated to other ethnic
populations.
Conclusion
This study showed that both decreased circulating C3 levels and
mesangial C3 deposition were independently associated with poor
renal outcome in patients with IgAN. These findings suggest that
systemic and local activation of complement may play a role in the
progression of IgAN and decreased serum C3 levels and mesangial
C3 deposition may have prognostic value in the management of
these patients.
Author Contributions
Performed the experiments: BJL HJJ. Analyzed the data: HJO DEY DHS
MJL FMD. Contributed reagents/materials/analysis tools: JTP THY
SWK KHC. Wrote the paper: SJK HMK SHH.
References
1. D’Amico G (1987) The commonest glomerulonephritis in the world: IgA
nephropathy. Q J Med 64: 709–727.
2. D’Amico G, Colasanti G, Barbiano di Belgioioso G, Fellin G, Ragni A, et al.
(1987) Long-term follow-up of IgA mesangial nephropathy: clinico-histological
study in 374 patients. Semin Nephrol 7: 355–358.
3. Li PK, Ho KK, Szeto CC, Yu L, Lai FM (2002) Prognostic indicators of IgA
nephropathy in the Chinese–clinical and pathological perspectives. Nephrol Dial
Transplant 17: 64–69.
4. D’Amico G (2004) Natural history of idiopathic IgA nephropathy and factors
predictive of disease outcome. Semin Nephrol 24: 179–196.
5. Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, et al. (2010) Histopathologic
features aid in predicting risk for progression of IgA nephropathy. Clin J Am Soc
Nephrol 5: 425–430.
6. Oortwijn BD, Eijgenraam JW, Rastaldi MP, Roos A, Daha MR, et al. (2008)
The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol
28: 58–65.
7. Hiemstra PS, Gorter A, Stuurman ME, Van Es LA, Daha MR (1987) Activation
of the alternative pathway of complement by human serum IgA. Eur J Immunol
17: 321–326.
8. Stad RK, Bruijn JA, van Gijlswijk-Janssen DJ, van Es LA, Daha MR (1993) An
acute model for IgA-mediated glomerular inflammation in rats induced by
monoclonal polymeric rat IgA antibodies. Clin Exp Immunol 92: 514–521.
9. Nakagawa H, Suzuki S, Haneda M, Gejyo F, Kikkawa R (2000) Significance of
glomerular deposition of C3c and C3d in IgA nephropathy. Am J Nephrol 20:
122–128.
10. Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M (1998) Glomerular
deposition of mannose-binding lectin (MBL) indicates a novel mechanism of
complement activation in IgA nephropathy. Nephrol Dial Transplant 13: 1984–
1990.
11. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, et al. (2006)
Glomerular activation of the lectin pathway of complement in IgA nephropathy
is associated with more severe renal disease. J Am Soc Nephrol 17: 1724–1734.
12. Espinosa M, Ortega R, Gomez-Carrasco JM, Lopez-Rubio F, Lopez-Andreu M,
et al. (2009) Mesangial C4d deposition: a new prognostic factor in IgA
nephropathy. Nephrol Dial Transplant 24: 886–891.
13. Wyatt RJ, Kanayama Y, Julian BA, Negoro N, Sugimoto S, et al. (1987)
Complement activation in IgA nephropathy. Kidney Int 31: 1019–1023.
14. Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, et al. (1997) Activated
complement C3: a potentially novel predictor of progressive IgA nephropathy.
Kidney Int 51: 1257–1264.
15. Nasr SH, D’Agati VD (2011) IgA-dominant postinfectious glomerulonephritis: a
new twist on an old disease. Nephron Clin Pract 119: c18–25; discussion c26.
16. Giannakakis K, Faraggiana T (2011) Histopathology of lupus nephritis. Clin Rev
Allergy Immunol 40: 170–180.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more
accurate method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study Group.
Ann Intern Med 130: 461–470.
18. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, et al. (2009) The
Oxford classification of IgA nephropathy: rationale, clinicopathological
correlations, and classification. Kidney Int 76: 534–545.
19. Kim JK, Kim JH, Lee SC, Kang EW, Chang TI, et al. (2012) Clinical features
and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc
Nephrol 7: 427–436.
20. Floege J, Feehally J (2000) IgA nephropathy: recent developments. J Am Soc
Nephrol 11: 2395–2403.
21. Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, et al. (2004) Relationship
between serum IgA/C3 ratio and progression of IgA nephropathy. Intern Med
43: 1023–1028.
22. Radford MG Jr., Donadio JV Jr., Bergstralh EJ, Grande JP (1997) Predicting
renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199–207.
23. Myllymaki JM, Honkanen TT, Syrjanen JT, Helin HJ, Rantala IS, et al. (2007)
Severity of tubulointerstitial inflammation and prognosis in immunoglobulin A
nephropathy. Kidney Int 71: 343–348.
24. Janssen U, Bahlmann F, Kohl J, Zwirner J, Haubitz M, et al. (2000) Activation
of the acute phase response and complement C3 in patients with IgA
nephropathy. Am J Kidney Dis 35: 21–28.
25. Tsokos GC (2004) Exploring complement activation to develop biomarkers for
systemic lupus erythematosus. Arthritis Rheum 50: 3404–3407.
26. Tomino Y, Suzuki S, Imai H, Saito T, Kawamura T, et al. (2000) Measurement
of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy
prior to renal biopsy. J Clin Lab Anal 14: 220–223.
27. van der Boog PJ, van Kooten C, van Seggelen A, Mallat M, Klar-Mohamad N,
et al. (2004) An increased polymeric IgA level is not a prognostic marker for
progressive IgA nephropathy. Nephrol Dial Transplant 19: 2487–2493.
28. Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, et al. (1986)
Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int 30:
924–931.
29. Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, et al. (2008)
Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA
nephropathy. J Am Soc Nephrol 19: 1008–1014.
30. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, et al. (2011) The
pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795–1803.
31. Cook HT, Botto M (2006) Mechanisms of Disease: the complement system and
the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2:
330–337.
Figure 9. The decline rate of eGFR. Error bars indicate standard
error.
doi:10.1371/journal.pone.0040495.g009
Complement Activation in IgA Nephropathy
PLoS ONE | www.plosone.org 12 July 2012 | Volume 7 | Issue 7 | e40495
32. Ammitzboll CG, Thiel S, Ellingsen T, Deleuran B, Jorgensen A, et al. (2011)
Levels of lectin pathway proteins in plasma and synovial fluid of rheumatoid
arthritis and osteoarthritis. Rheumatol Int.
33. Ohsawa I, Inoshita H, Ishii M, Kusaba G, Sato N, et al. (2010) Metabolic
impact on serum levels of complement component 3 in Japanese patients. J Clin
Lab Anal 24: 113–118.
34. Hernandez-Mijares A, Jarabo-Bueno MM, Lopez-Ruiz A, Sola-Izquierdo E,
Morillas-Arino C, et al. (2007) Levels of C3 in patients with severe, morbid and
extreme obesity: its relationship to insulin resistance and different cardiovascular
risk factors. Int J Obes (Lond) 31: 927–932.
35. Palmblad J, Fohlin L, Norberg R (1979) Plasma levels of complement factors 3
and 4, orosomucoid and opsonic functions in anorexia nervosa. Acta Paediatr
Scand 68: 617–618.
36. Sigal LH, Snyder BK (1989) Low serum complement levels in anorexia nervosa.
Am J Dis Child 143: 1391–1392.
37. Flierl MA, Gaudiani JL, Sabel AL, Long CS, Stahel PF, et al. (2011)
Complement C3 serum levels in anorexia nervosa: a potential biomarker for the
severity of disease? Ann Gen Psychiatry 10: 16.
38. Roufosse CA, Cook HT (2009) Pathological predictors of prognosis in
immunoglobulin A nephropathy: a review. Curr Opin Nephrol Hypertens 18:
212–219.
39. Chan LY, Leung JC, Lai KN (2004) Novel mechanisms of tubulointerstitial
injury in IgA nephropathy: a new therapeutic paradigm in the prevention of
progressive renal failure. Clin Exp Nephrol 8: 297–303.
40. Kusaba G, Ohsawa I, Ishii M, Inoshita H, Takagi M, et al. (2012) Significance
of broad distribution of electron-dense deposits in patients with IgA
nephropathy. Med Mol Morphol 45: 29–34.
41. El Karoui K, Hill GS, Karras A, Jacquot C, Moulonguet L, et al. (2012) A
clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.
J Am Soc Nephrol 23: 137–148.
42. Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, et al. (2010) The
complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus
19: 1272–1280.
43. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, et al.
(2003) A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 18:
1541–1548.
Complement Activation in IgA Nephropathy
PLoS ONE | www.plosone.org 13 July 2012 | Volume 7 | Issue 7 | e40495
